About Seagen Company
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Pfizer CFO Reiterates Seagen Closing Expected Later This Year, Early Next Year
Unusual Options Activity: LEGN, SGEN and Others Attract Market Bets, LEGN V/OI Ratio Reaches 1000.0
EST Nov 27th Closing Delivery - In the last 3 hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Daiichi Sankyo Wins Favorable Final Arbitration Ruling in Dispute With Seagen
Daiichi Sankyo (TYO:4568) received a favorable final arbitration ruling in an intellectual property dispute with Seagen, according to a Monday bourse filing. Seagen was ordered to pay about $45.5 mill
ColumnsOptions Market Statistics: Amazon Stock Plunges as US Accuses Online Giant of Illegal Monopoly, Options Pop
$Tesla(TSLA.US)$shares fell by 1.16%, closing at $244.12. Its options trading volume is 1.41 million. Call contracts account for 52.0% of the whole trading volume. The most traded calls are contracts of $260 strike price that expire on September 29th. The total volume reaches 61,279 with an open interest of 6,183. The most traded puts are contracts of a $250 strike price tha...
(Shares of the British pharmaceutical company gained more than 2.7% in premarket trading after the company reported positive results for its drug Dato-DXd in a trial for treating a common type of breast cancer.)
(Shares gained more than 2% after Bernstein upgraded home merchandiser to market perform from underperform. The firm cited improving revenue gr...
— Shares of the British pharmaceutical company gained more $Wayfair(W.US)$ than 2.7% in premarket trading after the company reported positive results for its drug Dato-DXd in a trial for treating a common type of breast cancer.
— Shares gained more than 2% after Bernstein upgraded home merchandiser to market perform from underperform. The firm cited improving revenue growth and margin commentary.